miRNA therapeutics in precision oncology: a natural premium to nurture [0.03%]
精准肿瘤学中的微小核糖核酸治疗：一个值得培养的自然优势
Chakresh Kumar Jain,Poornima Srivastava,Amit Kumar Pandey et al.
Chakresh Kumar Jain et al.
The dynamic spectrum of microRNA (miRNA) has grown significantly over the years with its identification and exploration in cancer therapeutics and is currently identified as an important resource for innovative strategies due to its functio...
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors [0.03%]
靶向RAF/RAS/MEK/ERK和BCL-2的个性化分子治疗在多发性骨髓瘤中的应用尝试
Vincenzo Raimondi,Nicolas Thomas Iannozzi,Jessica Burroughs-Garcìa et al.
Vincenzo Raimondi et al.
Multiple myeloma (MM) is a blood cancer that derives from plasma cells (PCs), which will accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat this disease that is still uncurable. The therapies used to t...
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy [0.03%]
肝内胆管癌的基因组改变：临床意义及其对治疗的相关性
Marianeve Carotenuto,Alessandra Sacco,Laura Forgione et al.
Marianeve Carotenuto et al.
Improving the survival of patients with cholangiocarcinoma (CCA) has long proved challenging, although the treatment of this disease nowadays is on advancement. The historical invariability of survival outcomes and the limited number of age...
Wang Chen,Yonghui Ma,Xiaoxuan Liu et al.
Wang Chen et al.
Messenger RNA (mRNA) has recently made important progress in clinical implementation, offering a promising therapeutic option for infectious disease and cancer. However, the nature of mRNA molecules rendered them poorly bioavailable and uns...
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic [0.03%]
PI3K/Akt/mTOR信号通路介导内分泌耐药的作用及临床应用
Aglaia Skolariki,Jamie D&#x;Costa,Martin Little et al.
Aglaia Skolariki et al.
The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and c...
Antibody-drug conjugates: beyond current approvals and potential future strategies [0.03%]
抗体偶联药物：获批现状及未来策略展望
Siddharth Menon,Sagun Parakh,Andrew M Scott et al.
Siddharth Menon et al.
The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic c...
Yeast as a tool to decipher the molecular mechanisms underlying the functions of Bcl-2 family [0.03%]
酵母揭秘Bcl-2族分子功能的分子机制
Stéphen Manon
Stéphen Manon
The budding yeast Saccharomyces cerevisiae, a favorite model in biology, does not contain any protein of the Bcl-2 family. From initial experiments with two-hybrid systems to the heterologous expression of human Bcl-2 family members, and th...
Advancing antibody-drug conjugates in gynecological malignancies: myth or reality? [0.03%]
抗体偶联药物在妇科恶性肿瘤中的应用：神话还是现实？
Marta Nerone,Maria Del Grande,Cristiana Sessa et al.
Marta Nerone et al.
Antibody-drug conjugates (ADCs) represent a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies to the cytotoxicity of classic chemotherapy agents. These dr...
Federica Papaccio
Federica Papaccio
Possible applications of salvianolic acid B against different cancers [0.03%]
羟基 salvianolic 酸 B 在不同癌症中的潜在应用
Iram Shahzadi,Zain Ali,Sidra Bukhari et al.
Iram Shahzadi et al.
Cancer is the second death causing disease worldwide after cardiovascular abnormalities. The difficulty in treating tumor cells with more precise targeted interventions and recurrence of cancer after treatment may pose great difficulty in d...